Evaluating pS2 Protein in Breast Cancer
Author Information
Author(s): M. Gion, R. Mione, G.L. Pappagallo, C. Gatti, O. Nascimben, M. Bari, A.E. Leon, O. Vinante, G. Bruscagnin
Primary Institution: Center for the Study of Biological Markers of Malignancy, General Regional Hospital, Venice
Hypothesis
Does pS2 provide additional prognostic information in breast cancer beyond steroid receptor status?
Conclusion
pS2 likely offers additional biological information to steroid receptor status in primary breast cancer patients.
Supporting Evidence
- pS2 was not correlated to age, tumor size, or nodal status.
- pS2 levels were higher in pre-menopausal women compared to peri- and post-menopausal women.
- pS2+ cases showed longer relapse-free survival and overall survival compared to pS2- cases.
- pS2 is an independent prognostic factor after nodal status.
Takeaway
This study looked at a protein called pS2 in breast cancer to see if it helps doctors understand how serious the cancer is, especially when other tests are not clear.
Methodology
The study measured pS2 protein levels in breast cancer samples using an immunoradiometric assay and evaluated its relationship with clinical parameters.
Limitations
The study may not generalize to all breast cancer patients as it focused on specific stages and treatment histories.
Participant Demographics
The study included 446 patients with primary breast cancer, with 24.3% pre-menopausal, 8.1% peri-menopausal, and 67.7% post-menopausal.
Statistical Information
P-Value
P = 0.004 for OS, P = 0.016 for RFS
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website